Aclaris Therapeutics Inc
NASDAQ:ACRS
Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 75 full-time employees. The company went IPO on 2015-10-07. The firm is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The firm is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. The company is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 75 full-time employees. The company went IPO on 2015-10-07. The firm is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The firm is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. The company is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.
Program Focus: Aclaris will advance ATI-2138, its dual ITK/JAK3 inhibitor, into a proof-of-concept Phase II study in moderate to severe atopic dermatitis.
Cost Discipline: The company emphasized strong cost containment, with nonrecurring expenditures in Q1 and significantly reduced cash burn expected for the rest of 2024.
Financial Position: Aclaris ended Q1 with $161 million in cash, cash equivalents, and marketable securities, and has zero debt.
Clinical Design: The Phase IIa atopic dermatitis trial will be an open-label, 12-week study in 15 patients, focusing on both efficacy and pharmacodynamic markers.
Differentiation: Management highlighted ATI-2138's unique dual mechanism and potential safety advantages compared to other JAK inhibitors, aiming for best-in-class status.
Strategic Flexibility: The company continues to evaluate strategic options and business development opportunities to generate non-dilutive capital.
